AI assistant
CSL Ltd. Board/Management Information 2006
17854_rns_2006-05-31_bb6bf1bd-ecae-41b2-9512-e4c3374de9c3.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Biopharmaceuticals for Life®
1 June 2006
CSL LIMITED
CSL APPOINTS NEW DIRECTOR
CSL today announced that Professor John Shine has been appointed a Director of the Company and will join the CSL Board effective immediately.
Professor John Shine is Executive Director of the Garvan Institute of Medical Research, Professor of Medicine and Professor of Molecular Biology at the University of NSW, Chairman of the National Health and Medical Research Council and a Vice-President of the Australian Academy of Science.
CSL's Chairman, Mr Peter Wade, said that he was delighted that Professor Shine had accepted the appointment to the Board and how much he was looking forward to working with Professor Shine, whose broad research experience in the field of medicine and molecular biology will be of great potential benefit for CSL as the company increases its investment in innovative research and development in these fields.
About CSL Limited
Headquartered in Melbourne, CSL Limited (ASX: CSL) is a global, specialty biopharmaceutical company that develops, manufactures and markets products to treat and prevent serious human medical conditions.
For further information, please contact:
Media Contacts:
Dr Rachel David Director of Public Affairs Phone: 0401 775 779 Email: [email protected]
Investor Contact:
Mark Dehring Director of Investor Relations Phone: 61 3 9389 2818 Email: [email protected]